Navigation Links
Saladax Biomedical, Inc. Completes $9 Million Debt Financing With GE Capital
Date:6/21/2011

BETHLEHEM, Pa., June 21, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today the completion of a $9 million debt financing with GE Capital.  

The secured term loan facility will be used for commercialization of the company's My5-FU™ assay, the first of Saladax's innovative dose management tests commercially available in the European Union (EU) and Australia as a convenient diagnostic kit that measures levels of 5-flourouracil, a widely used chemotherapy drug administered in conjunction with other drugs in therapy for colorectal cancer and other solid tumors.  The funds will also be used for further development of the company's additional assays.

"We are pleased to welcome GE Capital as an investor in the company," said Edward L. Erickson, president and CEO of Saladax.  "This loan facility will enable Saladax to continue developing and commercializing novel diagnostic products to achieve the promise of personalized medicine today."

Peter Gibson, vice president at GE Capital, Healthcare Financial Services – Life Science Finance, said, "Given that drug optimization through dose management has not been prevalent in oncology, we're delighted to invest in Saladax as the company has already achieved tangible results in this area.  We look forward to working with the Saladax as it continues expanding into additional markets worldwide."

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life.  The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is available in the United States from Myriad Genetics, sold by Saladax in Europe and will be distributed in Japan by FALCO biosystems.  Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds.  For more information, visit www.saladax.com.

About GE Capital, Healthcare Financial Services

With over $17 billion invested in more than 40 sub-sectors including senior housing, hospitals, pharmaceuticals, and medical devices, GE Capital, Healthcare Financial Services is a premier provider of capital and services to the healthcare industry.  Our team of professionals provides deep industry expertise to create business and financial solutions tailored to meet the individual needs of our customers.  The Life Science Finance team has worked with more than 500 companies throughout the United States, Canada and Europe.  With a dedicated focus on assisting life science companies large and small, from the first venture round to post-IPO, the team has provided over $2.5 billion in financing to the market.  For more information, visit gecapital.com/healthcare.

Saladax Biomedical, Inc.

Edward L. Erickson
President and Chief Executive Officer
eerickson@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
2. Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
3. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
4. BINDER BIOMEDICAL, INC. Announces Official Launch of the NEWTON™ Intervertebral Body Fusion Spinal Spacer System
5. Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
(Date:5/12/2017)... China and Canada joint tech company Laughing Face ... and detergent, and features a powerful disinfection process. The ... that washes and sanitizes women,s panties or babies, cloth diapers in ... ... require an external water inlet. ...
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... May 27, 2017 , ... In any business, follow up is critical ... your dental team at presenting treatment, there will always be some patients who can’t ... and money on best practices when it comes to presenting treatment. After the ...
(Date:5/27/2017)... Santa Rosa, CA (PRWEB) , ... May 27, 2017 , ... ... show cause for concern, but a new study from the Osteoarthritis Initiative ... vulnerable to developing knee osteoarthritis. Knowing this in advance may give doctors the opportunity ...
(Date:5/26/2017)... ... May 26, 2017 , ... The American Parkinson Disease Association’s ... eighty-nine grant submissions all vying for nearly $1,000,000 in funding that will be ... The American Parkinson Disease Association (APDA) is focused on advancing scientific research that ...
(Date:5/26/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) ... legislative activity and the latest regulatory concerns impacting RBMA members. The Legislative Education ... will continue through Monday, Sept. 11, at the Ritz-Carlton, Tysons Corner in Mclean, ...
(Date:5/26/2017)... Clara, Calif. (PRWEB) , ... May 26, 2017 ... ... announces the integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware ... provides a consistent, browser-based interface for diagnostic device operations. With this platform, initializing ...
Breaking Medicine News(10 mins):